Daela Xhema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daela Xhema has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Perota
Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
1 shared publication Benoît Lengele
UCLouvain IREC, Morphol Lab MORF, Ave Emmanuel Mounier 52-B1 52-04, B-1200 Brussels, Belgium
1 shared publication- Catherine Behets
Pole of Morphology, institut de recherche expérimentale et clinique (IREC), université catholique de Louvain (UCLouvain), Brussels, Belgium
1 shared publication Cesare Galli
Pig For Life, Marche-en-Famenne 6900, Belgium
1 shared publicationIrina Lagutina
Laboratorio di Tecnologie della Riproduzione, Avantea, Cremona 26100, Italy
1 shared publication- Jean Boisson
ENSTA Paris Tech, Dept Mech Engn, IMSIA, Palaiseau, Paris, France
1 shared publication
Latest Publications
- Open Access
- 4 November 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (46)
Double transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy
To be clinically efficient, beta cell replacement therapies such as pig islet xenotransplantation must ensure sufficient insulin secretion from grafted islets. While protection from host immune reaction is essential for islet engraftment and their subsequent functioning, intrinsic physiological properties of used cells are also a key factor. We have previously shown that islets with adenoviral-mediated expression of a dipeptidyl peptidase-resistant form of glucagon-like-peptide-1 (GLP-1) and a constitutively activated form of type 3 muscarinic receptor (M3R) in their beta cells have greatly improved insulin secretory response to glucose stimulation that is otherwise 4 to 10 times lower than human islets. Here, we describe in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the GLP-1M3R cassette under the porcine insulin promoter (InsGLP-1M3R), and their usage to treat insulin-dependent diabetes in an immunodeficient mouse model. Our results show that InsGLP-1M3R islets isolated from neonatal and adult pigs secrete up to 15-fold more insulin in response to glucose stimulation compared to wild-type (WT) islets. They also proved to be more efficient in treating diabetes in a preclinical model as shown by a significantly higher percentage of normoglycemic recipients and higher porcine C-peptide levels up to 9 mo post implantation.
- 4 November 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (46)
Open AccessDouble transgenic neonatal porcine islets as an alternative source for beta cell replacement therapy
To be clinically efficient, beta cell replacement therapies such as pig islet xenotransplantation must ensure sufficient insulin secretion from grafted islets. While protection from host immune reaction is essential for islet engraftment and their subsequent functioning, intrinsic physiological properties of used cells are also a key factor. We have previously shown that islets with adenoviral-mediated expression of a dipeptidyl peptidase-resistant form of glucagon-like-peptide-1 (GLP-1) and a constitutively activated form of type 3 muscarinic receptor (M3R) in their beta cells have greatly improved insulin secretory response to glucose stimulation that is otherwise 4 to 10 times lower than human islets. Here, we describe in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the GLP-1M3R cassette under the porcine insulin promoter (InsGLP-1M3R), and their usage to treat insulin-dependent diabetes in an immunodeficient mouse model. Our results show that InsGLP-1M3R islets isolated from neonatal and adult pigs secrete up to 15-fold more insulin in response to glucose stimulation compared to wild-type (WT) islets. They also proved to be more efficient in treating diabetes in a preclinical model as shown by a significantly higher percentage of normoglycemic recipients and higher porcine C-peptide levels up to 9 mo post implantation.
- 2 August 2024
- Published by Elsevier in Biomaterials
- Vol. 312, 122741
HLA Awareness in tissue decellularization: A paradigm shift for enhanced biocompatibility, studied on the model of the human fascia lata graft
- 2 August 2024
- Published by Elsevier in Biomaterials
- Vol. 312, 122741
HLA Awareness in tissue decellularization: A paradigm shift for enhanced biocompatibility, studied on the model of the human fascia lata graft